{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:06:28Z","timestamp":1792785988684,"version":"4.5.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Society for the Promotion of Science KAKENHI","award":["JP23K15888"],"award-info":[{"award-number":["JP23K15888"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are an important treatment option for recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC). However, some patients experience rapid disease progression shortly after ICI initiation, potentially resulting in deterioration of general condition and limited opportunities for subsequent treatment. This study investigated clinicopathological factors associated with early progression after ICI initiation in patients with R\/M HNSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 207 patients with R\/M HNSCC treated with nivolumab or pembrolizumab at a single institution. Early progression was defined as disease progression within 90\u00a0days after ICI initiation. Associations between clinicopathological factors and early progression were evaluated using logistic regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Early progression was observed in 80 patients (38.6%). In an exploratory survival comparison, patients with early progression had significantly shorter overall survival than those without early progression. Early progression rates increased from distant-only disease to locoregional-only disease and combined locoregional and distant disease. In multivariable analysis, combined locoregional, and distant disease showed the strongest independent association with early progression. Elevated neutrophil-to-lymphocyte ratio and hypoalbuminemia were also independently associated with early progression. In contrast, treatment regimen, treatment line, number of lesions, and bulky disease were not significantly associated with early progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Disease distribution was associated with early progression after ICI initiation in patients with R\/M HNSCC, with combined locoregional and distant disease showing the strongest independent association. These findings suggest that both disease status and host condition may influence failure to achieve adequate disease control shortly after ICI initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag167","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:09:34Z","timestamp":1789384174000},"source":"Crossref","is-referenced-by-count":2,"title":["Early progression after immune checkpoint inhibitor therapy in recurrent or metastatic head and neck squamous cell carcinoma: association with disease distribution in a single-center retrospective study"],"prefix":"10.1093","author":[{"given":"Hiroki","family":"Noda","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Makino","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Naoi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuo","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2026092508202108800_ref1","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"2026092508202108800_ref2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"2026092508202108800_ref3","doi-asserted-by":"publisher","first-page":"e70369","DOI":"10.1002\/cnr2.70369","article-title":"Real-world outcomes of immune checkpoint inhibitors in head and neck squamous cell carcinoma: Analyzing patient-specific factors influencing survival and response rate","volume":"8","author":"Huber","year":"2025","journal-title":"Cancer Rep (Hoboken)"},{"key":"2026092508202108800_ref4","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.3390\/ijms20112674","article-title":"Hyperprogression under immunotherapy","volume":"20","author":"Frelaut","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026092508202108800_ref5","doi-asserted-by":"publisher","first-page":"18215","DOI":"10.1007\/s00432-023-05504-5","article-title":"A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors","volume":"149","author":"Kang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026092508202108800_ref6","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.3390\/cancers16234056","article-title":"Immune-modified Glasgow prognostic score predicts therapeutic effect of pembrolizumab in recurrent and metastatic head and neck cancer","volume":"16","author":"Ueda","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026092508202108800_ref7","doi-asserted-by":"publisher","first-page":"28255","DOI":"10.1038\/s41598-024-79130-7","article-title":"Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in recurrent\/metastatic head and neck cancer treated with pembrolizumab","volume":"14","author":"Kasahara","year":"2024","journal-title":"Sci Rep"},{"key":"2026092508202108800_ref8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026092508202108800_ref9","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1007\/s10147-021-01965-1","article-title":"Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"26","author":"Nishimura","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"2026092508202108800_ref10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med"},{"key":"2026092508202108800_ref11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026092508202108800_ref12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11864-011-0176-y","article-title":"Current treatment options for metastatic head and neck cancer","volume":"13","author":"Price","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"2026092508202108800_ref13","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1002\/hed.25737","article-title":"Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer","volume":"41","author":"Yasumatsu","year":"2019","journal-title":"Head Neck"},{"key":"2026092508202108800_ref14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1186\/s12885-022-09809-5","article-title":"Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort","volume":"22","author":"Issa","year":"2022","journal-title":"BMC Cancer"},{"key":"2026092508202108800_ref15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.4103\/apjon.apjon-2145","article-title":"Understanding cachexia in head and neck cancer","volume":"8","author":"Muthanandam","year":"2021","journal-title":"Asia Pac J Oncol Nurs"},{"key":"2026092508202108800_ref16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.oraloncology.2017.07.023","article-title":"A randomized, open-label, phase III clinical trial of nivolumab versus therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: a subanalysis of Asian patients versus the global population in CheckMate 141","volume":"73","author":"Kiyota","year":"2017","journal-title":"Oral Oncol"},{"key":"2026092508202108800_ref17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag167\/71395324\/hyag167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag167\/71395324\/hyag167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:20:27Z","timestamp":1790338827000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article\/doi\/10.1093\/jjco\/hyag167\/8835703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag167","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"hyag167"}}